Member Info for DonaldTrumpsWig

Nanomat - 'The closing price on Tuesday 12 December 2023 prior to the company's presentation was 134-136. Today's current price is 75-78 as I type - down some 43% in just over two months of silence. Do you think that this has gone unnoticed by potential partners?'

Do you seriously think that potential partners will give a toss about the daily SP? Or perhaps, do you think they will be more concerned with decades worth of scientific evidence including extensive PK data and 7 cohorts of in human clinical trial data?

I have no problem with well researched and argued points even if I disagree with them, it's what makes this board tick.

What I do have a problem with is mindless garbage such as ..... 'or they scrapping Phase 2 then price tanks probably to 10/20p, whilst directors chill with their fat salaries'

This is deliberately provocative, unresearched garbage and LSE really should put a stop to it.

In the words of Edmund Burke 'The only thing necessary for the triumph of evil is for good men to do nothing'. Therefore report all deliberately antagonistic posts. I have started doing this and in their defence, LSE have been very good at removing the garbage.

He mentioned phase 3 thus marking himself out as a totally clueless plank

Leave Touk alone.

I once read a book about the Vietnam war and when the helicopter gunships were flying into this particular base, the viet-cong had a sniper that always fired at the gunships as they came into land. He was such a terrible shot that the gunship pilots forbade their door gunners from taking him out because if they did the viet-cong might replace him with someone who could shoot straight.

And that is the perfect analogy for Derek and his TW instructed de-ramps.

Unless you are the bloke that was married to the head of M&A at BP who eavesdropped her conversations whilst they were both stuck at home during Covid

Unbeknown to her he then purchased stock in the company she was negotiating the acquisition of, which he subsequently sold at a massive profit when BP made the purchase public. Sadly, for him the SEC spotted it and he's a goner !! and the Mrs binned him too !!

Tredz is your lack of self-awareness so acute that you are unable to recognise how disgusting you are for admitting to short Avacta

Can you not see that to seek to profit financially from driving the share price down is effectively weakening a business that is attempting to improve outcomes for potentially millions of cancer sufferers ?

I'm guessing that neither you nor a member of your family has ever gone through chemotherapy, however, if karma is to be believed I suspect, sadly, that it won't be long before this happens.

Take a long hard look at yourself in the mirror

Spot on NFT

What everyone has to understand that if AVCT can raise the funds to see P2 through then the increase in value will dwarf the current SP. It doesn't matter where the funds come from, it only matters that we can fund P2, preferably retaining full control/ownership of AVA6k

This is where the FUDsters let themselves down and expose their lack of business acumen. They constantly 'warn' that a pending raise is a bad thing, when it is actually the opposite if it funds P2

I for one would be perfectly happy to see the SP stall for the next 6 months in the full understanding that the upside will then be many multiples higher once P2 efficacy is completed.

Look at this logically. Best case scenario we have sufficient funds to take this through P2 and good efficacy data underpins the P1a data, what value a AVCT Pre/Cison T/O ?

For the purpose of this forecast let’s say $5bn or circa £18 per share. (£5 billion divided by 288 million shares)

If the thing that seems to be panicking all the bed wetters happens and the Co ask for another £20 million to complete P2.

Let’s assume an issue price of 50p then the issued share capital would add 40 million and become 328 million shares.

If then as said earlier the Co was able to complete P2 and demonstrate efficacy then the £5 billion enterprise value would be equivalent to circa £15.30 per share.

My point, are any genuine LTHs really going to lose sleep tonight over the difference between £18 (no raise) and £15.30 (with a 40 million share issue) on completion of P2/proof of efficacy?

Surely far far far more important that P2 is completed with or without raise and what value to SH’s if the Co can keep control for as long as possible?

In this case, the fear of a raise is significantly worse than the reality

Derek, your post of 12.55 is full of so much made-up nonsense I really feel compelled to break it down so that anyone not conversant with the science can, in future, discount anything that you ever post.

I have repeatedly challenged the science...Really, could you provide a sensible example where you have challenged the science?

The results from P1 so far pretty much prove safety but the insignificant number of patients data that has been published has not convinced the market or BP. - When you say 'insignificant number of patients' is this in your opinion? or are you a member of the SDMC for the ALS-6000-101 dose escalation phase 1 clinical trial.? Do you have a link to company or clinical trial data that clearly outlines the optimum number of patients required for this specific trial? Or are you working on the principle that like a good bag of chips, the more the better? Trials are designed to follow established protocols and to provide pre-determined levels of data. The number of patients per cohort is pre-determined and well established. Do you really think they make it up as they go along? Then at the end of the trial all look at each other and say 'oh bugger, the data is insufficient because we didn't test enough people?? we should of roped a few more in then we'd have been fine?? best start again'

You are correct that the Market remains to be convinced but your assertation that BP remain to be convinced is simply a made up statement with no basis in fact. Please don't confuse the fact that we haven't heard anything to mean that they aren't interested.

HENCE p1 continues. Al has intimated that nothing pivotal will happen until end of fortnightly testing. - Where has AS said that? link please, or is this another made-up assumption?

PS.

Sometimes cancer tumours just start shrinking of their own accord. Very small likelihood but that may have been our lucky patient that is held up as proof beyond doubt that AVA6000 is a winner. - Derek that is simply foolish nonsense, do you really think that AVCT would claim that the 65% guy had seen his improvement as a result of his inclusion in the AVA6k trial, when actually it was because his tumour had 'started shrinking of its own accord' and actually he was just a 'lucky patient'

'Most trial look for several hundred or more.' -

World renowned clinical trial expert Professor Egbert NDN Thorn once again demonstrating his excruciating lack of understanding of the difference between the trial of a novel therapeutic Vs Pre/Cision which is fundamentally a delivery mechanism.

Funding & delays, the two cornerstones of the Fudsters playbook.

Impossible to prove that there is a problem with either funding or delays therefore perfect topics for spreading fear.

Whilst enduring the current onslaught of old and new posters spreading guesswork and supposition about funding and C7 status etc etc, ask yourself one very simple question;

How many of the FUDsters comment on the veracity of the science? When do they ever challenge the trial results? the early efficacy results? the content of the SD and P1a presentations?

They don't, because to do so would pin them down to facts and data and they don't want that as they can be challenged and would almost certainly be exposed for their lack of knowledge and understanding.

They need supposition and guesswork, fear can only exist within the vacuum of the unknown, within the uncertainty of the open question.

It's very tough at the moment and I would completely agree that is beyond time for the Co to provide an update but never forget updates work both ways and if there were problems, delays, funding shortages etc the Co are legally bound to tell us....and as yet, they haven't

Are we there yet Mummy ?

Perhaps those pesky cancer sufferers aren't queueing up at MSK shouting test me, test me, test me. Grow up and show some common sense and patience. We will receive an update via RNS when one is ready not when you and Eggy need a nappy change.

Read the RNS's to answer your question. The only reliable source of information regarding trial status.

Please note - no pre-existing bias was used when presenting this response.

Morphosis lead candidiate is Tafasitamab which 'binds to a protein called CD19, which is found on most B cells (a type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Tafasitamab is a type of monoclonal antibody. Also called Monjuvi.'

A MAB based targeted cancer therapy. If only there was a simpler, cheaper, broader reach way to target cancer cells, maybe with a snazzy name ..like...oh ..maybe something like ..Pre/Cision. I wonder how much that might be worth?

Not on my PC Tim (sad face and turd emoji)

'If you don't want to be bothered by pigeons...don't feed them!!!' - Brilliant analogy Bella (laughing face and thumbs up emoji)

'But it hasn't yet proven that it's clinically effective and how that level of effectiveness compares to standard Dox. Which is what people will want to know before signing over billions of dollars to Avacta. For that you need a Phase 2 drug trial'

Thank goodness we have the world renowned clinical trial specialist Professor Egbert-NDN-Thorn advising us on trial protocols. Those idiots on the SDMC at Avacta don't know what they are talking about.

Absolutely nothing, zero, nada has changed with the fundamentals since we were at £1.60 last October, except sentiment.

The potential, the opportunity the paradigm shift in cancer treatment is exactly the same as when we were e-high-fiving after the SD and P1a read out. As Eliot Forster said 'we know what we've got'

Ignore the SP and remain patient and for those that like a good conspiracy theory, it's always good to re-post an old favourite which perhaps becomes more pertinent as the silence continues (especially point 1)

https://www.griproom.com/fun/10-signs-your-company-is-about-to-be-acquired

Having reflected that yesterday those mad rampers dominated the board, perhaps it is only fair and in the interest of balance that we recognise our resident 'realists' (Wyn, Eggy, Derek, & Sheppy) and highlight some of their concerns. for example:

We don't know for sure that the FAP present in arthritis will cause AVA600 to cleave in patients hands and not in the TME?

It's OK for rampers to focus on the science but what about the charts? They say we could go to 40p ? and the charts are never wrong?

What about the LFT and the house purchase? he lied to us about those and therefore he must be lying to us about the AVA6k P1a trial results.

I'm sure there are other genuine, well researched claims that our resident FUDsters would like us to consider in the interest of balance

You have to assume that having Christina Coughlin based in the US with her extensive experience would ensure that we are expediting all necessary protocols to achieve FDA/ODD status. That, coupled with Simon Bennett negotiating all deals gives me great confidence that we have the right people with the right experience in the right places at the right time.

Ducks lining up.